The clustering of cardiovascular risk factors was noted already a century ago, but it is only recently that a link between the CV risk cluster and insulin resistance has been postulated – a proposal which is not unanimously accepted. There is no doubt, however, that obesity per se impacts on renal function and the risk of chronic kidney disease (CKD). Particularly obesity early in life is an important predictor of CKD in adult life, but in adults as well a high body mass index (BMI) is an independent predictor of ESRD. The BMI threshold is lower in Asians. The link between obesity and CKD is not fully explained by the association between obesity and diabetes or hypertension respectively. Obesity is associated with increased glomerular filtration rate and renal blood flow, glomerulomegaly and in extreme cases focal segmental glomerulosclerosis. The causal role of obesity is underlined by the effect of weight loss on proteinuria and glomerular hyperfiltration. An even better predictor than BMI is visceral obesity (waist circumference). For kidney disease in the metabolic syndrome it is relevant that insulin resistance is linked to salt sensitivity and increased tubular reabsorption of sodium. Recent evidence points to adverse effects of aldosterone on podocytes, mediated by reactive oxygen species and resulting from hypothetical stimulants of aldosterone synthesis by visceral adipocytes.

Keywords:
Metabolic syndrome, Obesity, Hyperfiltration, Insulin resistance, Aldosterone, Microalbuminuria
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.